Menu

Congress Agrees to Give NIH $2 Billion Extra

The proposed spending plan for 2017 includes money for Alzheimer’s and cancer research.

May 1, 2017
Kerry Grens

WIKIMEDIA, O.J.Update (May 8): On Friday (May 5), President Trump accounced that he signed the spending package into law.

Late Sunday night (April 30), members of Congress reached a bipartisan deal for government spending through September of this year that included an additional $2 billion over current appropriations for the National Institutes of Health. According to STAT News, $400 million of that amount will be directed toward Alzheimer’s research and another $476 million will go to the National Cancer Institute.

“The spending agreement is a firm repudiation of the Trump administration’s vision of a much leaner federal research program,” STAT reported. The president’s proposal for 2018 funding would include an 18 percent cut to the NIH.

The $2 billion boost for the NIH comes as part of legislation allocating $1.1 trillion across the government. According to Bloomberg, the legislation also includes $42 million extra for the Department of Energy’s Office of Science and $15 million more for DOE’s Advanced Research Projects Agency–Energy.

Science advocacy organizations supported this omnibus package. The Federation of American Societies for Experimental Biology (FASEB), for instance, stated on its website April 19: “The FY 2017 omnibus appropriations bill is critical. Not only will it keep federal agencies operating through September 30, 2017, but it also includes a significant increase for the National Institutes of Health and additional funding for the National Science Foundation and Department of Agriculture research programs.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
INTEGRA has responded to customers’ requests and developed two new 24-channel pipetting heads, extending the capabilities of its popular VIAFLO 96/384.
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.